VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRMDIRadimed Corporation
$82.31$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. IRMD
  4. Financial Ratios

IRadimed Corporation (IRMD) Financial Ratios

Latest Ratios: P/E Ratio 44.2x · EV/EBITDA 32.7x · ROE 24.8%. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

IRMD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.1B$1.3B$703M$604M$357M$582M$284M$287M$296M$178M$133M
Enterprise Value$1.0B$1.2B$651M$556M$302M$522M$236M$246M$268M$159M$115M
P/E Ratio →44.1955.5936.6735.1627.7462.45207.2729.9747.04378.7518.50
P/S Ratio11.7814.929.609.216.7113.918.947.459.737.694.10
P/B Ratio11.1813.228.108.464.858.064.625.177.065.394.17
P/FCF40.5572.7839.90110.6643.7755.3354.7529.4541.6568.5316.88
P/OCF42.1850.1227.4444.8535.6051.6848.7628.0540.1651.9814.15

P/E links to full P/E history page with 30-year chart

IRMD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—14.318.898.485.6612.497.456.408.816.903.55
EV / EBITDA32.6743.9128.5826.7418.5146.53405.4724.9237.7361.4410.33
EV / EBIT38.2842.2926.8225.5918.6553.10—28.5143.27114.1210.53
EV / FCF—69.8036.95101.9136.9449.6745.6125.2937.7161.5014.64

IRMD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin76.7%76.7%76.9%76.5%77.4%76.6%74.3%77.1%76.3%75.9%81.1%
Operating Margin31.2%31.2%30.0%30.6%29.3%23.5%-2.4%22.5%19.7%5.6%33.6%
Net Profit Margin26.8%26.8%26.3%26.2%24.1%22.3%4.3%25.0%20.7%2.2%22.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE24.8%24.8%24.3%23.7%17.6%14.0%2.3%19.8%16.8%1.5%22.6%
ROA21.7%21.7%20.2%19.4%15.2%12.1%2.0%16.7%14.4%1.3%19.9%
ROIC50.2%50.2%56.4%72.2%76.7%55.2%-3.9%44.9%31.4%6.7%61.3%
ROCE27.8%27.8%26.5%26.2%20.4%13.8%-1.2%16.5%15.3%3.8%33.2%

IRMD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity——0.000.030.030.030.040.05———
Debt / EBITDA——0.010.100.140.224.660.30———
Net Debt / Equity—-0.54-0.60-0.67-0.76-0.82-0.77-0.73-0.67-0.55-0.56
Net Debt / EBITDA-1.87-1.87-2.29-2.29-3.42-5.30-81.26-4.10-3.94-7.02-1.59
Debt / FCF—-2.98-2.96-8.74-6.83-5.66-9.14-4.16-3.94-7.03-2.25
Interest Coverage———————————

Net cash position: cash ($51M) exceeds total debt ($0)

IRMD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio7.987.988.844.659.0611.1812.9610.069.508.619.33
Quick Ratio6.846.847.623.878.4310.5412.169.448.637.588.27
Cash Ratio5.035.036.143.056.789.1610.577.897.336.467.01
Asset Turnover—0.770.740.710.620.500.450.580.630.590.87
Inventory Turnover1.681.681.621.202.242.272.072.421.781.321.58
Days Sales Outstanding—59.5252.6168.0690.9044.8452.6569.1150.4859.7642.41

IRMD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield1.4%1.2%1.9%2.2%3.5%——————
Payout Ratio66.9%66.9%71.1%76.9%97.9%——————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield2.3%1.8%2.7%2.8%3.6%1.6%0.5%3.3%2.1%0.3%5.4%
FCF Yield2.5%1.4%2.5%0.9%2.3%1.8%1.8%3.4%2.4%1.5%5.9%
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.1%1.0%7.5%
Total Shareholder Yield1.4%1.2%1.9%2.2%3.5%0.0%0.0%0.0%0.1%1.0%7.5%
Shares Outstanding—$13M$13M$13M$13M$13M$12M$12M$12M$12M$12M

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Launch-driven margin pressure and guidance credibility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Demand Sustained Compounding

Based on reported figures, IRMD trades at 49.3x trailing P/E and 36.9x EV/EBITDA, a premium that presumes its recurring disposable revenue can keep compounding despite recent quarterly growth volatility.

Compared with its own 2024 quarterly history, the multiple has not been supported by a matching acceleration in top-line growth, since year-over-year revenue growth fell to roughly 0.3% in Q2 2026 before recovering. The PEG of 0.67 appears low only if forward earnings growth proves durable, which the recent EPS miss makes less certain. Relative to the peer set, where several names carry negative earnings, the premium reflects investor willingness to pay for profitability rather than a cheap valuation on any absolute basis.

Structural Margins Anchored by Niche Pricing

Gross margin has held between roughly 74% and 78% across ten quarters, while net margin of 26.9% in Q3 2026 suggests the high-margin model is intact even after the Q2 2026 pressure point.

The narrow gross margin band indicates that pricing power in the MRI-compatible niche is stable rather than episodic, which supports treating gross margin as the most reliable indicator of earning power. Operating margin of 33.6% in Q3 2026 versus 31.2% in Q2 suggests operating leverage is real but uneven, likely reflecting launch costs for the 3870 platform. Investors should monitor whether the Q2 dip proves transitory or indicates that the next-generation product carries structurally higher expense intensity.

Returns Diluted by Idle Cash Balance

ROIC has oscillated between roughly 11% and 14% over the period, with the Q3 2026 reading of 14.2% suggesting returns remain solid but are partly suppressed by a large non-operating cash balance.

The ROE of 6.2% and ROA of 5.5% in Q3 2026 appear modest relative to the operating margin, which points to a balance sheet where cash accounts for a large share of total assets. This implies that the return metrics understate the economics of the operating business while still reflecting a conservative capital allocation stance. The ROIC trend has not clearly compounded, so the case for rising returns depends on the company deploying its cash productively, which the reported data does not yet demonstrate.

Working Capital Stable but Receivables Lumpy

Days sales outstanding has held near 50 to 56 days and inventory days near 51 to 63, while the cash conversion cycle has ranged from roughly 212 to 325 days, suggesting working capital is steady but sensitive to quarterly timing.

The consistency of DSO and DIO implies stable collection and inventory practices, yet the cash conversion cycle appears inflated mainly by the payables component, which has been reported as swinging between roughly 190 and 288 days. Because the payables-based figures are unusually large relative to the other drivers, the cycle may be more a function of how the supplied data is structured than of operational leverage over suppliers. Analysts should treat the CCC as a directional signal and verify the payables definition before drawing conclusions about supplier financing.

Liquidity Far Exceeds Operating Needs

A current ratio near 9.0 and quick ratio of 9.0 in Q3 2026, with no reported debt, suggest liquidity is abundant relative to the company's current obligations, though the excess cash may reflect limited deployment.

Because inventory is a small share of current assets, the quick and current ratios converge, indicating that liquidity does not depend on converting inventory under stress. Even under a severe demand shock, the reported cash position would appear sufficient to cover near-term obligations, though the supplied data does not disclose stress scenarios directly. The more relevant question for investors is whether management can deploy this liquidity into growth or returns, since an unusually large idle balance can weigh on per-share economics.

Return on Equity Misleads on a Cash-Heavy Balance Sheet

ROE and ROA appear depressed in part because roughly half of total assets sits in cash, so these ratios may understate the operating economics investors are paying for at a 49x P/E.

Applying ROE to a business where equity is dominated by idle cash compresses the metric and makes the company look less profitable than its 27% net margin implies. A more informative lens is ROIC on operating capital or after-tax operating income relative to invested operating assets, which better isolates the productivity of the core franchise. Investors should be cautious about inferring weak capital efficiency from ROE alone, since that conclusion reflects the balance sheet structure rather than the economics of the disposable revenue model.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open IRMD Terminal

IRMD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IRMD — Frequently Asked Questions

Quick answers to the most common questions about buying IRMD stock.

What is IRadimed Corporation's P/E ratio?

IRadimed Corporation's current P/E ratio is 44.2x. The historical average is 42.4x. This places it at the 50th percentile of its historical range.

What is IRadimed Corporation's EV/EBITDA?

IRadimed Corporation's current EV/EBITDA is 32.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 33.2x.

What is IRadimed Corporation's ROE?

IRadimed Corporation's return on equity (ROE) is 24.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 20.5%.

Is IRMD stock overvalued?

Based on historical data, IRadimed Corporation is trading at a P/E of 44.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is IRadimed Corporation's dividend yield?

IRadimed Corporation's current dividend yield is 1.42% with a payout ratio of 66.9%.

What are IRadimed Corporation's profit margins?

IRadimed Corporation has 76.7% gross margin and 31.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.